<DOC>
	<DOCNO>NCT00310154</DOCNO>
	<brief_summary>RATIONALE : Gefitinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving gefitinib together docetaxel radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose docetaxel give together gefitinib radiation therapy treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Gefitinib , Docetaxel , Radiation Therapy Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose docetaxel safely deliver combination gefitinib definitive course 3-D planned thoracic radiotherapy patient stage III non-small cell lung cancer . OUTLINE : This dose-escalation study docetaxel . - Chemoradiotherapy : Patients receive concurrent chemoradiotherapy comprise docetaxel IV 30 minute day 1 thoracic radiotherapy daily day 1-5 week 1-7 absence disease progression unacceptable toxicity . - Consolidation chemotherapy : Beginning 2 week completion chemoradiotherapy , patient receive consolidation chemotherapy comprise docetaxel IV 60 minute day 1 22 . - Gefitinib therapy : Patients also receive oral gefitinib daily begin start chemoradiotherapy continue 1 year* absence disease progression . NOTE : *Patients continue receive gefitinib 2-week rest period chemoradiotherapy consolidation chemotherapy . Cohorts 3-6 patient receive escalate dos docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Tumor tissue test determine correlation epidermal growth factor receptor presence response treatment . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 45 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) , include follow : Squamous cell carcinoma Adenocarcinoma ( include bronchoalveolar cell ) Large cell anaplastic carcinoma ( include giant clear cell carcinoma ) Stage IIIA/B disease Unresectable disease Tumors adjacent vertebral body allow No demonstrable bone invasion All gross disease must able encompassed radiation boost field accordance homogeneity criterion Contralateral mediastinal disease ( N3 ) allow gross disease encompass radiation boost field accordance homogeneity criteria No scalene , supraclavicular , contralateral hilar node involvement Pleural effusion allow transudate , cytologically negative , nonbloody AND tumor encompass within reasonable field radiotherapy No exudative , bloody , cytologically malignant effusion Pleural effusion see chest CT scan chest xray small tap allow Measurable disease , define lesion accurately measure ≥ 1 dimension ( long diameter record ) ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan No nonmeasurable disease , include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Abdominal mass confirm followed imaging technique Cystic lesion Tumor lesion situate previously irradiate area PATIENT CHARACTERISTICS : ECOG performance status 01 Granulocyte count ≥ 1,500/mm^3 Hemoglobin &gt; 8.0 g/dL Platelet count ≥ 100,000/mm^3 Bilirubin &lt; 1.5 mg/dL Creatinine &lt; 1.5 time upper limit normal ( ULN ) Meets 1 follow criterion : AST ALT &lt; 2 time ULN AST ALT ≤ 2.5 time ULN AND alkaline phosphatase ( AP ) normal AST ALT normal AND AP ≤ 4 time ULN FEV_1 ≥ 1.2 L No currently active malignancy except nonmelanoma skin cancer Patients consider another currently active malignancy complete therapy malignancy consider physician &lt; 30 % risk relapse ( i.e. , treatment earlystage prostate cancer ) Not pregnant nursing Fertile patient must use effective contraception 3 month complete treatment No history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No know severe hypersensitivity gefitinib excipients product No evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) No evidence significant clinical disorder laboratory find would limit compliance study requirement No evidence clinically active interstitial lung disease ( asymptomatic , chronic stable radiographic change allow ) No peripheral neuropathy ≥ grade 1 PRIOR CONCURRENT THERAPY : At least 2 week since prior formal exploratory thoracotomy No prior chemotherapy radiotherapy NSCLC No prior epidermal growth factortargeting drug ( i.e. , gefitinib , erlotinib , cetuximab ) No investigational agent within 30 day study entry No concurrent phenytoin , carbamazepine , rifampicin , barbiturate , Hypericum perforatum ( St John 's wort ) No concurrent hormonal therapy chemotherapy except follow : Steroids adrenal failure , allergic reaction , septic shock Hormones nondiseaserelated condition ( e.g. , insulin diabetes ) Glucocorticosteroids antiemetic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>